Cancer immune resistance: can theories converge?
Authors:
Open Access
- 12 December 2017
- journal article
- review article
- Published by Portland Press Ltd. in Emerging Topics in Life Sciences
- Vol. 1 (5) , 411-419
Abstract
Immune oncology (IO) is challenged to expand its usefulness to a broader range of cancers. A second generation of IO agents acting beyond the realm of Checkpoint Inhibitor Therapy (CIT) is sought with the intent of turning immune-resistant cancers into appealing IO targets. The published literature proposes a profusion of models to explain cancer immune resistance to CIT that largely outnumber the immune landscapes and corresponding resistance mechanisms. In spite of the complex and contradicting models suggested to explain refractoriness to CIT, the identification of prevailing mechanisms and their targeting may not be as daunting as it at first appears. Here, we suggest that cancer cells go through a conserved evolutionary bottleneck facing a Two-Option Choice to evade recognition by the immune competent host: they can either adopt a clean oncogenic process devoid of immunogenic stimuli (immune-silent tumors) or display an entropic biology prone to immune recognition (immune-active tumors) but resilient to rejection thanks to the recruitment of compensatory immune suppressive processes. Strategies aimed at enhancing the effectiveness of CIT will be different according to the immune landscape targeted.Keywords
This publication has 120 references indexed in Scilit:
- Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse modelJournal of Experimental Medicine, 2013
- IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cellsJournal of Experimental Medicine, 2012
- Inflammasomes in carcinogenesis and anticancer immune responsesNature Immunology, 2012
- Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic MelanomaClinical Cancer Research, 2011
- Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and RadiotherapyThe Cancer Journal, 2011
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- The immunologic aspects of poxvirus oncolytic therapyCancer Immunology, Immunotherapy, 2009
- Specificity in cancer immunotherapySeminars in Immunology, 2008
- Transferable anticancer innate immunity in spontaneous regression/complete resistance miceProceedings of the National Academy of Sciences, 2006